MiaSara Perez Salvá

Ms. MiaSara Perez Salvá

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2026 in Nanomaterials
Verified
Journal Article
Open access
PDF file
CWChristine Wu
Christine Wu
KAKatherine E Ayala
Katherine E Ayala
SCSolimar Collazo-Hernandez
Solimar Collazo-Hernandez
MiaSara Perez SalváMiaSara Perez Salvá
MiaSara Perez Salvá
NMNataniel Medina-Berríos
Nataniel Medina-Berríos
BWBrad Weiner
Brad Weiner
Carbon-based quantum dots and their nitrogen- and sulfur-doped derivatives were used as platforms to improve the aqueous solubility for Paclitaxel, Violacein and Tetrandrine, drugs with known high partition coefficients (Log P). Paclitaxel, Violacein and Tetrandrine showed a significant reduction in their partition coefficient values by coupling with the carbon-based quantum dots. Paclitaxel’s partition coefficient value decreased from 3.96 to 0.2, Violacein’s from 3.34 to 1.17, and Tetrandrine’s from 2.5 to 1.57, thus demonstrating a significant reduction in their hydrophobicity without being encapsulated. The efficiency of each type of carbon-based quantum dot in lowering each drug’s Log P varied and this behavior was correlated with the nature of the surface interaction between each drug and each of the carbon-based quantum dots.

24 May 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JJJose Alejandro Lozada Jerez
Jose Alejandro Lozada Jerez
ALAlexis Lavin
Alexis Lavin
JJJose Alejandro Lozada Jerez
Jose Alejandro Lozada Jerez
MiaSara Perez SalváMiaSara Perez Salvá
MiaSara Perez Salvá
FRFabiola Rosa-Suárez
Fabiola Rosa-Suárez
BWBrad Weiner
Brad Weiner
Background/Objectives: Andrographolide (ADG) is a plant-derived compound with promising anticancer properties, but its medical use is limited due to poor water solubility and low bioavailability. This study proposes developing a gold-based nanocomposite drug delivery system, using a simplified synthesis method, to improve ADG’s hydrophilicity and enhance its delivery efficiency. Methods: A one-step method was used to synthesize gold nanocomposites with carbon quantum dots (CBQDs) and doped CBQDs acting as reducing and stabilizing agents. These nanocomposites were then conjugated with ADG and thoroughly characterized using multiple structural and spectroscopic techniques such as X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), ultraviolet–visible spectroscopy (UV–Vis), transmission electron microscopy (TEM), Raman spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy. Hydrophilicity enhancement was evaluated using NMR-based log P measurements. Biological assessment involved cell viability assays and confocal microscopy studies in PC3 prostate cancer cells, along with the morphological evaluation of human red blood cells. Results: XRD confirmed the formation of crystalline, face-centered cubic gold nanoparticles, while spectroscopic analyses verified successful nanocomposite formation and ADG conjugation. NMR results showed enhanced hydrophilicity of ADG. Biological tests demonstrated that the nanocomposites were compatible with cells. Conclusions: This study presents a straightforward strategy for synthesizing gold-based nanocomposites that enhance the hydrophilicity and delivery potential of andrographolide, supporting their applicability as nanocarrier platforms for anticancer drug delivery.

25 August 2026 in Diseases
Verified
Journal Article
Open access
PDF file
MiaSara Perez SalváMiaSara Perez Salvá
MiaSara Perez Salvá
CRCarolyn Marie Ruiz-Perez
Carolyn Marie Ruiz-Perez
AVAlondra Veloz-Bonilla
Alondra Veloz-Bonilla
RRRocío K Rivera-Valentín
Rocío K Rivera-Valentín
Background/Objectives: Pediatric solid tumors (PST) are a biologically distinct group of malignancies whose developmental origins and molecular drivers differ substantially from those of adult cancers, with direct implications for therapeutic strategy and clinical outcome. This review synthesizes current evidence on molecular pathogenesis, tumor microenvironment biology, and the structural conditions that shape access to care across select PST. Methods: A narrative review of peer-reviewed literature was conducted primarily using PubMed, supplemented by Google Scholar, covering publications from 2000 to 2025. Tumor types were selected based on their prevalence in the pediatric population and the availability of evidence addressing both molecular features and health disparities. Body: Across eight tumor types (neuroblastoma, Ewing sarcoma, pediatric brain tumors, rhabdomyosarcoma, Wilms tumor, retinoblastoma, osteosarcoma, and chondrosarcoma), recurrent molecular alterations including MYCN amplification, EWS-FLI1 fusions, PAX-FOXO1 rearrangements and IDH 1/2 mutations emerge as central determinants of disease behavior and eligibility for treatment. The tumor microenvironment manifests as a shared mediator of immune exclusion and therapeutic resistance across tumor types, with, but not limited to, tumor-associated macrophages, myeloid-derived suppressor cells, and checkpoint molecule expression, identified as recurrent features influencing treatment response. Immunotherapeutic strategies have shown variable efficacy across PST, with the most consistent clinical benefit established in neuroblastoma. A critical and underappreciated pattern stands out across tumor types: children carrying the most aggressive molecular subtypes are disproportionately those with the least access to therapies those subtypes demand, emphasizing an overlap of biological and structural disadvantage that is also amplified in low- and middle-income countries, where late-stage presentation, treatment abandonment and limited access to molecular diagnostics compound the biological disadvantage. Conclusions: Within the eight PST reviewed, the most aggressive molecular subtypes and the greatest structural disadvantages converge in the same children; those carrying MYCN amplification, PAX-FOXO1 fusions, or EWS-FLI1 fusions are disproportionately those with the least access to the therapies their biology demands. Genomic and immunologic advances will only reach their full clinical potential when paired with inclusive trial data, diversified genomic databases, and most importantly, equitable access to biomarker-specialized therapies across all populations.